Selonsertib

Research use only, not for human use.

Selonsertib (GS-4997)?is a highly selective and potent, ATP-competetive inhibitor of ASK1 (Apoptosis Signal-regulating Kinase 1,?MAP3K5) with potential anti-inflammatory, antineoplastic and anti-fibrotic activities; orally bioavailable.

Selonsertib (GS-4997)?is a highly selective and potent, ATP-competetive inhibitor of ASK1 (Apoptosis Signal-regulating Kinase 1,?MAP3K5) with potential anti-inflammatory, antineoplastic and anti-fibrotic activities; orally bioavailable. Steatohepatitis,Phase 3 Clinical(In Vitro):Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis. Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain.

Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis. Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain.

——

GS-4997 | GS4997 | GS 4997

MAPK/ERK Signaling

MEK

ASK1

Other Indications

Steatohepatitis

1448428-04-3

445.4921

C24H24FN7O

>98% (HPLC)

DMSO: ≥ 31 mg/mL

CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F

Benzamide, 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-[6-[4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]-2-pyridinyl]-

(-20℃)

With Ice Pack

≥ 2 years